Literature DB >> 1530996

Brain natriuretic peptide as a cardiac hormone in essential hypertension.

M Kohno1, T Horio, K Yokokawa, K Murakawa, K Yasunari, K Akioka, A Tahara, I Toda, K Takeuchi, N Kurihara.   

Abstract

PURPOSE: A natriuretic peptide, brain natriuretic peptide (BNP), has been isolated from porcine hearts. We performed this study to determine if BNP is secreted from the heart and to identify changes, if any, in the plasma BNP concentration in essential hypertension. PATIENTS AND METHODS: We measured the immunoreactive (ir) BNP concentration at intracardiac sites including the coronary sinus of five patients with heart disease during cardiac catheterization. We examined plasma ir-BNP in 48 hypertensive patients, 15 borderline hypertensive patients, and 25 normotensive subjects.
RESULTS: Plasma ir-BNP in the coronary sinus was greater than at other cardiac sites. The concentration was significantly higher in hypertensive subjects than in borderline hypertensive or normotensive subjects. Hypertensive patients with left ventricular hypertrophy (LVH) established by echocardiography had higher plasma ir-BNP levels than those without LVH. In the hypertensive group, plasma ir-BNP was closely correlated with the LV mass index. In these patients, BNP levels were correlated with mean arterial pressure and inversely correlated with the LV ejection fraction, although these correlations were weak. Reverse-phase high-pressure liquid chromatography showed that the major component of circulating ir-BNP in the hypertensive and normotensive subjects corresponded to authentic human BNP-32.
CONCLUSIONS: Human BNP-32 was secreted through the coronary sinus from the heart and may act as a cardiac hormone. Plasma BNP was increased in many of the hypertensive subjects with LVH. The increase in BNP seemed to be related to LVH or the cardiac overload associated with LVH.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1530996     DOI: 10.1016/0002-9343(92)90011-y

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  30 in total

1.  Remodeling of the peripheral cardiac conduction system in response to pressure overload.

Authors:  Brett S Harris; Catalin F Baicu; Nicole Haghshenas; Harinath Kasiganesan; Dimitri Scholz; Mary S Rackley; Lucile Miquerol; Daniel Gros; Rupak Mukherjee; Terrence X O'Brien
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-03       Impact factor: 4.733

2.  Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure.

Authors:  S Kasama; T Toyama; T Hatori; H Sumino; H Kumakura; Y Takayama; S Ichikawa; T Suzuki; M Kurabayashi
Journal:  Heart       Date:  2005-09-13       Impact factor: 5.994

3.  Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure.

Authors:  S Kasama; T Toyama; T Hatori; H Sumino; H Kumakura; Y Takayama; S Ichikawa; T Suzuki; M Kurabayashi
Journal:  Heart       Date:  2006-04-18       Impact factor: 5.994

4.  Evaluation of cardiac sympathetic nerve activity and aldosterone suppression in patients with acute decompensated heart failure on treatment containing intravenous atrial natriuretic peptide.

Authors:  Shu Kasama; Takuji Toyama; Toshiya Iwasaki; Hiroyuki Sumino; Hisao Kumakura; Kazutomo Minami; Shuichi Ichikawa; Naoya Matsumoto; Tomoaki Nakata; Masahiko Kurabayashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-09       Impact factor: 9.236

5.  Increasing aminoterminal-pro-B-type natriuretic peptide precedes the development of arterial hypertension: the multiethnic study of atherosclerosis.

Authors:  Otto A Sanchez; David R Jacobs; Hossein Bahrami; Carmen A Peralta; Lori B Daniels; João A Lima; Alan Maisel; Daniel A Duprez
Journal:  J Hypertens       Date:  2015-05       Impact factor: 4.844

Review 6.  Cyclic nucleotide regulation of cardiac sympatho-vagal responsiveness.

Authors:  Dan Li; David J Paterson
Journal:  J Physiol       Date:  2016-05-05       Impact factor: 5.182

7.  Determinants of plasma brain natriuretic peptide levels in untreated hypertensive patients.

Authors:  Akiko Goda; Shinji Nakao; Takeshi Tsujino; Masao Yuba; Misato Otsuka; Mika Matsumoto; Chikako Yoshida; Yoshiro Naito; Masaaki Lee-Kawabata; Mitsumasa Ohyanagi; Tohru Masuyama
Journal:  J Echocardiogr       Date:  2011-04-01

8.  Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population.

Authors:  T A McDonagh; A D Cunningham; C E Morrison; J J McMurray; I Ford; J J Morton; H J Dargie
Journal:  Heart       Date:  2001-07       Impact factor: 5.994

9.  Suppression of Resting Metabolism by the Angiotensin AT2 Receptor.

Authors:  Nicole K Littlejohn; Henry L Keen; Benjamin J Weidemann; Kristin E Claflin; Kevin V Tobin; Kathleen R Markan; Sungmi Park; Meghan C Naber; Francoise A Gourronc; Nicole A Pearson; Xuebo Liu; Donald A Morgan; Aloysius J Klingelhutz; Matthew J Potthoff; Kamal Rahmouni; Curt D Sigmund; Justin L Grobe
Journal:  Cell Rep       Date:  2016-07-28       Impact factor: 9.423

10.  Atrial natriuretic factor significantly contributes to the mineralocorticoid escape phenomenon. Evidence for a guanylate cyclase-mediated pathway.

Authors:  N Yokota; B G Bruneau; M L Kuroski de Bold; A J de Bold
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.